Page last updated: 2024-10-15

rsva405

Description

RSVA405: an AMPK activator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135400298
CHEMBL ID381688
MeSH IDM0572058

Synonyms (21)

Synonym
CHEMBL381688
dndi1417286
n'-[(e)-[4-(diethylamino)-6-oxocyclohexa-2,4-dien-1-ylidene]methyl]pyridine-4-carbohydrazide
n'-[4-(diethylamino)-2-hydroxybenzylidene]isonicotinohydrazide
AG-690/33087040
AKOS001264387
140405-36-3
n-[(e)-[4-(diethylamino)-2-hydroxy-phenyl]methyleneamino]pyridine-4-carboxamide
rsva 405
rsva405
n'-{(e)-[4-(diethylamino)-2-hydroxyphenyl]methylidene}isonicotinohydrazide
n'-(4-(diethylamino)-2-hydroxybenzylidene)isonicotinohydrazide
2-[[4-(diethylamino)-2-hydroxyphenyl]methylene]hydrazide-4-pyridinecarboxylicacid
EX-A4384
F81729
MS-24558
HY-103238
CS-0026035
EN300-1212511
n'-{[4-(diethylamino)-2-hydroxyphenyl]methylidene}pyridine-4-carbohydrazide
Z49547568
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID258360Growth inhibition of chloroquine-resistant Plasmodium falciparum FcB1 at 1 uM2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Design, synthesis and in vitro antimalarial activity of an acylhydrazone library.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]